291 related articles for article (PubMed ID: 19403877)
1. Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study.
Fast S; Nielsen VE; Grupe P; Bonnema SJ; Hegedüs L
J Nucl Med; 2009 May; 50(5):732-7. PubMed ID: 19403877
[TBL] [Abstract][Full Text] [Related]
2. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
[TBL] [Abstract][Full Text] [Related]
3. Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake.
Ceccarelli C; Antonangeli L; Brozzi F; Bianchi F; Tonacchera M; Santini P; Mazzeo S; Bencivelli W; Pinchera A; Vitti P
Thyroid; 2011 Jul; 21(7):759-64. PubMed ID: 21568727
[TBL] [Abstract][Full Text] [Related]
4. Effect of recombinant human TSH on the uptake of radioactive iodine ((123)I) by the thyroid gland in healthy beagles.
Campos M; Peremans K; Duchateau L; Dobbeleir A; Vandermeulen E; van Hoek I; Paes G; Daminet S
Domest Anim Endocrinol; 2010 Nov; 39(4):215-21. PubMed ID: 20688462
[TBL] [Abstract][Full Text] [Related]
5. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter.
Huysmans DA; Nieuwlaat WA; Erdtsieck RJ; Schellekens AP; Bus JW; Bravenboer B; Hermus AR
J Clin Endocrinol Metab; 2000 Oct; 85(10):3592-6. PubMed ID: 11061507
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial.
Nielsen VE; Bonnema SJ; Boel-Jørgensen H; Veje A; Hegedüs L
J Clin Endocrinol Metab; 2005 Jan; 90(1):79-83. PubMed ID: 15494456
[TBL] [Abstract][Full Text] [Related]
7. Single, very low dose (0.03 mg) of recombinant human thyrotropin (rhTSH) effectively increases radioiodine uptake in the I-131 treatment of large nontoxic multinodular goiter.
Mojsak MN; Abdelrazek S; Szumowski P; Rogowski F; Sykała M; Kostecki J; Kociura-Sawicka A; Jurgilewicz D; Myśliwiec J
Nucl Med Rev Cent East Eur; 2016; 19(1):3-11. PubMed ID: 26841373
[TBL] [Abstract][Full Text] [Related]
8. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial.
Bonnema SJ; Nielsen VE; Boel-Jørgensen H; Grupe P; Andersen PB; Bastholt L; Hegedüs L
J Clin Endocrinol Metab; 2007 Sep; 92(9):3424-8. PubMed ID: 17566091
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter.
Giusti M; Cappi C; Santaniello B; Ceresola E; Augeri C; Lagasio C; Minuto F
Minerva Endocrinol; 2006 Sep; 31(3):191-209. PubMed ID: 17213787
[TBL] [Abstract][Full Text] [Related]
11. Significance of radioiodine uptake at 72 hours versus 24 hours after pretreatment with recombinant human thyrotropin for enhancement of radioiodine therapy in patients with symptomatic nontoxic or toxic multinodular goiter.
Duick DS; Baskin HJ
Endocr Pract; 2004; 10(3):253-60. PubMed ID: 15310544
[TBL] [Abstract][Full Text] [Related]
12. Dose-dependent acute effects of recombinant human TSH (rhTSH) on thyroid size and function: comparison of 0.1, 0.3 and 0.9 mg of rhTSH.
Fast S; Nielsen VE; Bonnema SJ; Hegedüs L
Clin Endocrinol (Oxf); 2010 Mar; 72(3):411-6. PubMed ID: 19508679
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT).
Czarnywojtek A; Czepczynski R; Ruchala M; Wasko R; Zgorzalewicz-Stachowiak M; Szczepanek E; Zamyslowska H; Bartkowiak Z; Florek E; Sowinski J
Neuro Endocrinol Lett; 2009; 30(2):209-14. PubMed ID: 19675515
[TBL] [Abstract][Full Text] [Related]
14. A 30-year perspective on radioiodine therapy of benign nontoxic multinodular goiter.
Bonnema SJ; Hegedüs L
Curr Opin Endocrinol Diabetes Obes; 2009 Oct; 16(5):379-84. PubMed ID: 19623060
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human TSH increases the efficacy of a fixed activity of radioiodine for treatment of multinodular goitre.
Cubas ER; Paz-Filho GJ; Olandoski M; Goedert CA; Woellner LC; Carvalho GA; Graf H
Int J Clin Pract; 2009 Apr; 63(4):583-90. PubMed ID: 18803554
[TBL] [Abstract][Full Text] [Related]
16. The effect of recombinant human tsh on the thyroid (123)i uptake in iodide treated normal subjects.
Lawrence JE; Emerson CH; Sullaway SL; Braverman LE
J Clin Endocrinol Metab; 2001 Jan; 86(1):437-40. PubMed ID: 11232037
[TBL] [Abstract][Full Text] [Related]
17. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter.
Nieuwlaat WA; Huysmans DA; van den Bosch HC; Sweep CG; Ross HA; Corstens FH; Hermus AR
J Clin Endocrinol Metab; 2003 Jul; 88(7):3121-9. PubMed ID: 12843153
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy.
Fast S; Hegedüs L; Grupe P; Nielsen VE; Bluhme C; Bastholt L; Bonnema SJ
J Clin Endocrinol Metab; 2010 Aug; 95(8):3719-25. PubMed ID: 20519346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
